Skip to main content
. 2016 Nov 29;107(11):1667–1676. doi: 10.1111/cas.13071

Figure 6.

Figure 6

Survival analysis for overall survival and recurrence‐free survival according to FGFR alteration status as determined by NGS. (a) Overall survival of patients with or without FGFR alteration for the whole population (n = 75). (b) Subset analysis of overall survival according to FGFR alteration status for lung squamous cell carcinoma patients with recurrence (n = 36). (c) Recurrence‐free survival of relapsed patients with or without FGFR alteration (n = 36).